Caplyta Shows Superior Efficacy, Weight Profile in MDD Meta-Analysis
JNJ sits 55% above its 52-week low of $146.115.
Summary
A new network meta-analysis revealed that Caplyta® (lumateperone) demonstrated the greatest improvement across key efficacy outcomes among adjunctive treatments for Major Depressive Disorder (MDD). The analysis further highlighted Caplyta's superior weight change profile, showing no weight gain compared to placebo plus antidepressant therapy, and a 100% probability of superiority on mean weight change versus all comparators. This strong comparative data provides a significant competitive advantage for Johnson & Johnson's Caplyta, reinforcing its profile as an effective and well-tolerated treatment in a large market. This positive clinical differentiation could support increased market share and sales for the drug, adding to the recent string of positive news for JNJ, including strong Q1 results and other drug development milestones.
At the time of this announcement, JNJ was trading at $226.49 on NYSE in the Life Sciences sector, with a market capitalization of approximately $546.9B. The 52-week trading range was $146.12 to $251.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.